Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sulphasalazine in rheumatic diseases

M Dougados1

  • 1René Descartes University, Department of Rheumatology, Hôpital Cochin Paris, France.

Agents and Actions. Supplements
|January 1, 1993
PubMed
Summary

Sulfasalazine, a drug used for inflammatory bowel disease, also benefits rheumatic conditions like rheumatoid arthritis. Its high gut concentration may explain its positive effects on joint symptoms, positioning it as a disease-modifying antirheumatic drug.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global health in axial spondyloarthritis: thresholds for the Assessment of SpondyloArthritis international Society Health Index and the EuroQol score: analysis of the ASAS-PerSpA study.

Scandinavian journal of rheumatology·2024
Same author

Performance of cut-offs of the ASAS Health Index to discriminate between treatment groups in patients with axial spondyloarthritis in the TICOSPA trial.

Seminars in arthritis and rheumatism·2024
Same author

Impact of pregnancy on sacroiliac imaging in women with axial spondyloarthritis: results of the analysis of the DESIR cohort.

Scandinavian journal of rheumatology·2024
Same author

[Implementation, of multidisciplinary consultations for patients with inflammatory arthritis and treated with subcutaneous biologic DMARDs: Assessment at one year and outlook].

Annales pharmaceutiques francaises·2022
Same author

The ASAS-OMERACT core domain set for axial spondyloarthritis.

Seminars in arthritis and rheumatism·2021
Same author

Unveiling axial involvement in psoriatic arthritis: An ancillary analysis of the ASAS-perSpA study.

Seminars in arthritis and rheumatism·2021

Area of Science:

  • Rheumatology and Gastroenterology
  • Pharmacology

Background:

  • Sulfasalazine has a 40-year history in treating inflammatory bowel diseases globally.
  • Since the late 1970s, sulfasalazine has demonstrated efficacy in managing rheumatic diseases, including rheumatoid arthritis and spondylarthropathy.

Purpose of the Study:

  • To explore the potential of sulfasalazine as a treatment for rheumatic diseases.
  • To investigate the role of gut concentration in sulfasalazine's therapeutic effects on articular symptoms.

Main Methods:

  • Review of existing literature on sulfasalazine's use in inflammatory bowel diseases and rheumatic conditions.
  • Analysis of proposed mechanisms of action, focusing on gastrointestinal drug concentrations.

Main Results:

  • Sulfasalazine exhibits positive effects in rheumatoid arthritis and spondylarthropathy.
  • High concentrations of sulfasalazine within the gut are hypothesized to contribute to its beneficial impact on joint symptoms.

Conclusions:

  • Sulfasalazine demonstrates disease-modifying properties in rheumatoid arthritis.
  • Sulfasalazine is likely a disease-modifying antirheumatic drug for spondylarthropathy, warranting further investigation.

Related Experiment Videos